Edison report: Reinvestment period with increased R&D focus  
    Edison report: Q1 23 cash flows in line with our estimates  
    New melanoma breakthrough by Kazia could potentially save thousands of lives  
    Edison report: PNOC022 trial expanded  
    Edison report: Doubling down on clinical development  
    Interim data from MSKCC study  
    GBM Agile Update  
    Kazia recognises GBM Awareness Day 2022 as it expands clinical trial activity in Europe and US  
    Kazia launches new SAB  
    Kazia paxalisib preclinical DIPG data released at IPSNO  
    Kazia's Alliance study progresses to expansion phase  
    Kazia presents final PII data at ASCO  
    GBM Agile opens to paxalisib in Europe  
    Edison Research: Deep Dive into Childhood Brain Cancer  
    Kazia to present at investor conferences hosted by HC Wainwright and LD Micro  
    Kazia marks DIPG Awareness Day  
    Interview with Dr Matt Dun for World DIPG Awareness Day  
    Kazia to present at ASCO  
    Kazia presents preclinical data for paxalisib at AACR  
    Kazia presents on EVT801 at AACR  
    Kazia to present at two conferences  
    First patient into Cornell keto study  
    Quarterly Activities Report And Appendix 4c  
    Kazia Corporate Presentation  
    Kazia Therapeutics To Present At Hc Wainwright Bioconnect Conference  
    Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer  
    Kazia Announces Positive Final Data From Phase Ii Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma  
    Gbm Agile Opens To Paxalisib In Canada  
    Kazia Therapeutics Appoints John Friend, Md, As Chief Medical Officer  
    Pnoc Study In Childhood Brain Cancer Enrols First Patient  
    Kazia Annual General Meeting Results  
    Kazia Annual General Meeting Results  
    Quarterly Activities Report And Appendix 4c  
    Kazia Therapeutics To Present At Hc Wainwright 23rd Annual Global Investment Conference  
    Evt801 Phase I Study Receives Full Regulatory Approval  
    Quarterly Activities Report And Appendix 4c  
    Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day  
    Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs  
    Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036  
    Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma  
    Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient  
    Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se  
    Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company  
    Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab  
    Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm  
    Kazia Therapeutics Limited Appendix 4D Half-year report